Elan Wins $55M From Abraxis In Cancer Drug Suit
Abraxis BioScience Inc. has vowed to challenge a jury verdict that awarded $55.2 million to plaintiff Elan Pharma International Ltd. and held that Abraxis' breast cancer drug Abraxane infringed on a...To view the full article, register now.
Already a subscriber? Click here to view full article